Retatrutide, a experimental dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising outcomes in early human assessments . Current examination suggests that retatrutide may offer substantial benefits for patients with type , particularly regarding body mass reduction a